maccura(SZ:300463) Xin Lang Zheng Quan·2025-08-29 02:05Summary of Key Points Core Viewpoint - The financial performance of Maike Biological is declining, with significant decreases in revenue and net profit, while the stock's financing and margin trading activities indicate a mixed sentiment among investors [1][2]. Group 1: Financial Performance - For the first half of 2025, Maike Biological reported a revenue of 1.075 billion yuan, a year-on-year decrease of 15.94% [2]. - The net profit attributable to shareholders for the same period was 34.04 million yuan, reflecting a substantial year-on-year decline of 83.12% [2]. Group 2: Stock Trading Activity - On August 28, Maike Biological's stock price fell by 1.04%, with a trading volume of 165 million yuan [1]. - The financing buy-in amount for the same day was 34.38 million yuan, while the financing repayment was 24.80 million yuan, resulting in a net financing buy of 9.58 million yuan [1]. - The total financing and margin trading balance for Maike Biological reached 343 million yuan, with the financing balance accounting for 4.53% of the circulating market value, which is below the 50th percentile of the past year [1]. Group 3: Shareholder and Dividend Information - As of June 30, 2025, the number of shareholders for Maike Biological was 35,000, a slight decrease of 0.18% from the previous period [2]. - The company has distributed a total of 1.278 billion yuan in dividends since its A-share listing, with 370 million yuan distributed over the last three years [3]. - The eighth largest circulating shareholder, Hong Kong Central Clearing Limited, reduced its holdings by 8.7749 million shares, holding 5.1207 million shares as of June 30, 2025 [3].